NIB101 / Noile-Immune Biotech - LARVOL DELTA

Study of NIB101 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=3 | Terminated | Sponsor: Noile-Immune Biotech, Inc | N=42 ➔ 3 | Trial completion date: Feb 2028 ➔ May 2025 | Recruiting ➔ Terminated | Trial primary completion date: Feb 2028 ➔ May 2025; due to the reconsideration of development strategy

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Solid Tumor

Study of NIB101 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Noile-Immune Biotech, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor